ID   21PT
AC   CVCL_7934
SY   21 PT
DR   Cell_Model_Passport; SIDM01900
DR   GEO; GSM1172937
DR   GEO; GSM1172849
DR   GEO; GSM3145689
DR   IARC_TP53; 3288
DR   LINCS_HMS; 51109
DR   PharmacoDB; 21PT_11_2019
DR   Wikidata; Q54583263
RX   DOI=10.1007/978-1-4612-0411-4_18;
RX   DOI=10.1016/B978-0-12-333530-2.50009-5;
RX   PubMed=1977518;
RX   PubMed=7923592;
RX   PubMed=8482634;
RX   PubMed=20458274;
RX   PubMed=24176112;
RX   PubMed=25960936;
WW   https://www.synapse.org/#!Synapse:syn2346643/wiki/62255
CC   Part of: JWGray breast cancer cell line panel.
CC   Characteristics: 21PT is non-tumorigenic whereas 21NT and 21MT-1/21-MT-2 cause tumors in the nude mice system.
CC   Doubling time: 35.5 +- 1.1 hours (Note=In alpha H&E medium), 42.3 +- 4.7 hours (Note=In D medium) (PubMed=8482634); 35.70 hours (JWGray panel).
CC   HLA typing: A*31:01,26:01; B*35:02,38:01; C*04:01,12:03; DRB1*04:03,04:03 (PubMed=25960936).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser33Phefs*9 (c.96_97insT); Zygosity=Unspecified (PubMed=7923592).
CC   Omics: Deep exome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Breast; UBERON=UBERON_0000310.
CC   Cell type: Epithelial cell of mammary gland; CL=CL_0002327.
DI   NCIt; C4872; Breast carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_7931 ! 21MT-1
OI   CVCL_7932 ! 21MT-2
OI   CVCL_7933 ! 21NT
OI   CVCL_IP81 ! H16F1
OI   CVCL_IP82 ! H16N-2
OI   CVCL_IP83 ! H16N-3
SX   Female
AG   36Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 22
//
RX   DOI=10.1007/978-1-4612-0411-4_18;
RA   Band V., Sager R.;
RT   "Tumor progression in breast cancer.";
RL   (In book chapter) Neoplastic transformation in human cell system. Mechanism of carcinogenesis; Rhim J.S., Dritschilo A. (eds.); pp.169-178; Humana Press; New York; USA (1990).
//
RX   DOI=10.1016/B978-0-12-333530-2.50009-5;
RA   Leibovitz A.;
RT   "Cell lines from human breast.";
RL   (In book chapter) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.161-184; Academic Press; New York; USA (1994).
//
RX   PubMed=1977518;
RA   Band V., Zajchowski D., Swisshelm K.L., Trask D.K., Kulesa V., Cohen C.,
RA   Connolly J.L., Sager R.;
RT   "Tumor progression in four mammary epithelial cell lines derived from
RT   the same patient.";
RL   Cancer Res. 50:7351-7357(1990).
//
RX   PubMed=7923592; DOI=10.1093/carcin/15.9.1969;
RA   Liu X.-L., Band H., Gao Q.-S., Wazer D.E., Chu Q.-M., Band V.;
RT   "Tumor cell-specific loss of p53 protein in a unique in vitro model of
RT   human breast tumor progression.";
RL   Carcinogenesis 15:1969-1973(1994).
//
RX   PubMed=8482634; DOI=10.1016/0360-3016(93)90176-V;
RA   Wazer D.E., Joyce M., Jung L., Band V.;
RT   "Alterations in growth phenotype and radiosensitivity after
RT   fractionated irradiation of breast carcinoma cells from a single
RT   patient.";
RL   Int. J. Radiat. Oncol. Biol. Phys. 26:81-88(1993).
//
RX   PubMed=20458274; DOI=10.1038/labinvest.2010.97;
RA   Souter L.H., Andrews J.D., Zhang G.-H., Cook A.C., Postenka C.O.,
RA   Al-Katib W., Leong H.S., Rodenhiser D.I., Chambers A.F., Tuck A.B.;
RT   "Human 21T breast epithelial cell lines mimic breast cancer
RT   progression in vivo and in vitro and show stage-specific gene
RT   expression patterns.";
RL   Lab. Invest. 90:1247-1258(2010).
//
RX   PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110; PMCID=PMC3937590;
RA   Daemen A., Griffith O.L., Heiser L.M., Wang N.J., Enache O.M.,
RA   Sanborn Z., Pepin F., Durinck S., Korkola J.E., Griffith M., Hur J.S.,
RA   Huh N., Chung J., Cope L., Fackler M.J., Umbricht C.B., Sukumar S.,
RA   Seth P., Sukhatme V.P., Jakkula L.R., Lu Y.-L., Mills G.B., Cho R.J.,
RA   Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.;
RT   "Modeling precision treatment of breast cancer.";
RL   Genome Biol. 14:R110.1-R110.14(2013).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893; PMCID=PMC4355981;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//